Trial · NCT01558687
Cilengitide Imaging Trial in Glioblastoma
NCT01558687, Phase 1, Terminated, Merck KGaA, Darmstadt, Germany
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cilengitide Imaging Trial in Glioblastoma. Trials, record NCT01558687. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01558687
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cilengitide Imaging Trial in Glioblastoma
- NCT number
- NCT01558687
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 1 participants, actual
- Lead sponsor
- Merck KGaA, Darmstadt, Germany
- Conditions
- Supratentorial Newly Diagnosed Inoperable Gliobastoma
- Interventions
- Drug (including placebo), Standard therapy
- First posted
- 2012-03-20
- Last updated
- 2014-02-04
- Other registries' IDs
- eudract:2011-003794-29
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate constant for passive contrast agent plasma/interstitium transfer (ktrans) | 2 weeks | Any change in tumor kinetic model parameter (maximum increase in ktrans) to assess the tumor microvasculature structure and function |
| Primary | Fractional blood plasma volume (vp) | 2 weeks | Any change in tumor kinetic model parameter (maximum change in vp) to assess the tumor microvasculature structure and function |
| Primary | Maximum tumor to brain ratio (TBRmax) | 2 weeks | Assessment of tumor amino acid (FET) uptake (tumor viability) |
| Secondary | Total tumor volume and enhancing tumor volume | 2 weeks | Change in total tumor volume and enhancing tumor volume as a measure of the overall level of tumor perfusion during the first 2 weeks of treatment with Cilengitide monotherapy |
| Secondary | Interstitial space volume fraction (putative contrast agent distribution volume) (=ve) | 2 weeks | Change in the tumor extravascular extracellular space volume during the first 2 weeks of treatment with Cilengitide monotherapy |
| Secondary | Apparent Diffusion coefficient (ADC) | 2 weeks | Change in perfusion parameter ADC during the first 2 weeks of treatment with Cilengitide monotherapy |
| Secondary | Fractional anisotropy (FA) | 2 weeks | Change in FA during the first 2 weeks of treatment with Cilengitide monotherapy |
| Secondary | Kinetic behavior of [18F]FET uptake | 2 weeks | Change in tumor amino acid (FET) uptake kinetics during the first 2 weeks of treatment with Cilengitide monotherapy |
| Secondary | Mean spin-lattice relaxation time of unbound protons in water | 2 weeks | Change in Absolute T1(mean spin-lattice relaxation time of unbound protons in water) during the first 2 weeks of treatment with Cilengitide monotherapy |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01558687
GET https://conductscience.org/api/trials/v1/NCT01558687/registered